Runaway inpatient spending in particular caused CVS’ insurance costs to snowball after returning “to patterns we have not seen since the start of the pandemic,” its CFO said.
CVS slashes 2024 outlook — again — as Medicare seniors drive spending Read More »
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
Neurocrine Biosciences on Tuesday won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
CEO Saum Sutaria says the health system is a “new company” following nine hospital sales in the first quarter.
Tenet raises full-year revenue guidance on $2.2B in Q1 profit Read More »
Despite being hit with a 20% sales decline due to a plunge in demand for its COVID-19 products, Pfizer on Wednesday reported $14.88 billion in revenue in the first quarter of 2024 exceeding analyst expectations.
Pfizer Beats Q1 Forecast Despite 20% Revenue Drop, Cuts Four Pipeline Programs Read More »
The Atlanta area is receiving more physical real estate options to foster its burgeoning biotech industry.
Atlanta’s Biotech Scene Prepares for New Heights Read More »
J&J and BMS’ challenges to Medicare drug price negotiations shut down in federal court less than a week after BMS announced it was laying off more than 2,000 employees.
This week’s legal losses by J&J and BMS reinforce the notion that Medicare drug price negotiation is here to stay, and investors continue to favor biologics over small molecules.
Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court Read More »
Altamira Therapeutics Ltd. today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.
GT Medical Technologies, Inc. today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy.
